Clinical Trial Update: Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating cabozantinib in combination with nivolumab for older patients with renal cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)
• OPDIVO (nivolumab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Kidney Cancer, Renal Cell Cancer | Phase 4 | Status: RECRUITING